Dr Ian Godsland is Wynn Reader in Human Metabolism at Imperial College London. He is undertaking long-term investigations into metabolic risk factors for diabetes and cardiovascular disease in the context of a range of studies, in particular a cohort study in which intensive metabolic investigations were carried out for 29 years. His main focus is on the measurement and definition of insulin resistance, insulin secretion and the metabolic syndrome, and their roles in type 2 diabetes and coronary heart disease. He also has an extensive background in metabolic risk factor changes associated with use of gonadal steroids,especially oral contraceptive and postmenopausal hormone replacement therapies.
et al., 2024, The importance of intravenous glucose tolerance test glucose stimulus for the evaluation of insulin secretion, Scientific Reports, ISSN:2045-2322
et al., 2024, A Randomized Controlled Trial Assessing the Impact of Continuous Glucose Monitoring with a Predictive Hypoglycemia Alert Function on Hypoglycemia in Physical Activity for People with Type 1 Diabetes (PACE)., Diabetes Technol Ther, Vol:26, Pages:95-102
et al., 2023, Prediction of Hypoglycaemia in the 24 Hours after Exercise in Adults with Type 1 Diabetes, 83rd Annual Scientific Sessions of the American-Diabetes-Association (ADA), AMER DIABETES ASSOC, ISSN:0012-1797
et al., 2023, Type 1 diabetes genetic risk scores do not impact partial remission status in autoantibody positive individuals within the first year of diagnosis: Data from ADDRESS-2, WILEY, ISSN:0742-3071
et al., 2023, PREDICTION OF HYPOGLYCAEMIA DURING EXERCISE IN PEOPLE WITH TYPE 1 DIABETES: DATA FROM THE PACE STUDY, MARY ANN LIEBERT, INC, Pages:A253-A253, ISSN:1520-9156